Published: May 08, 2017
CCS has renewed its commitment to CCTG through a major funding award of $23.5 million over 5 years.

From left to right: Janet Dancey, CCTG Director; Lynne Hudson, CCS President, and CEO; Richard Reznick, Dean of the Faculty of Health Sciences at Queen’s University.

The Canadian Cancer Society (CCS) has renewed its commitment to the Canadian Cancer Trials Group (CCTG) through a major funding award of $23.5 million over 5 years. This generous funding allows CCTG to continue its world-class cancer clinical trials research.

Published: April 05, 2017
Thanks to the Tragically Hip for their support of brain cancer research

Gord Sinclair, from left, and Rob Baker of The Tragically Hip, Janet Dancy, director of the Canadian Cancer Trials Group, and Lynne Hudson, president and CEO of the Canadian Cancer Society, at the unveiling of a plaque honouring The Hip.

The Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research. A commemorative plaque was presented to the band in honour of their support for cancer clinical trials at the Canadian Cancer Trials Group (CCTG).

CCTG, housed at Queen’s University in Kingston, is supported by a core grant from the Canadian Cancer Society.

Published: March 02, 2017
iRECIST - immunotherapy Response Evaluation Criteria in Solid Tumours

Immunotherapeutics trigger different response patterns in tumours than classic chemotherapy drugs.

A recent publication in The Lancet Oncology highlights the development, led by the RECIST Working Group, of iRECIST (immunotherapy Response Evaluation Criteria in Solid Tumours) consensus-based guideline, which addresses the novel characteristics of this new class of anticancer therapeutics, ensuring consistent trial design and data collection.

Published: February 09, 2017

Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the Canadian Clinical Trials Group Symptom Control Trial SC.23

Published: December 15, 2016

Dr. Rosalyn Juergens, the study chair of IND.226, gave an oral presentation of the experience to date on IND.226

Published: November 30, 2016

Two Canadian Cancer Trials Group (CCTG) Investigational New Drug (IND) trials – IND.221 and IND.226 – were presented today at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

Published: September 28, 2016

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy.

Published: August 23, 2016

On Saturday, September 17, the CCTG Trialblazers participated in the Canadian Cancer Society's Mudmoiselle Ladies' Mud Run held in Kingston. They raised over $2500 and had a blast doing it!

We would like to thank the Trialblazers team for their team spirit and willingness to get down and dirty in support of cancer research.

Published: September 20, 2016

The Canadian Cancer Trials Group was referenced in an articles on funds raised for brain cancer research by The Tragically Hip's summer tour.

Published: July 14, 2016

Dr. Chris O'Callaghan, at the Canadian Cancer Trials Group in Kingston, is a senior investigator in a new trial that produced effective results in improving the longevity and quality of life of patients with glioblastoma, an incurable brain cancer.